Fidelity MSCI Health Care Index ETF (FHLC)

On our desk, we are looking closely at the recent spike in short interest for FHLC, which jumped by 360.9% in July to 216,178 shares. Even though short interest represents only about 0.5% of total shares, the velocity of the move caught our attention given the fund's defensive low-beta profile of 0.60. With a days-to-cover ratio sitting at a lean 0.7 days, it's clear short-term traders are poking at the healthcare sector amid ongoing drug-pricing legislative headwinds.

From a risk management standpoint, FHLC continues to impress with its historical downside protection—posting a max drawdown of just -15.2% compared to the category average of -29.3%. However, sitting at a price around $84.66–$85.19, the fund's technical posture is somewhat fragile; it is hovering just 0.81% above its 200-day moving average of $69.82 (adjusted for scaling), making that baseline a crucial line in the sand for our systematic models.

Institutional sentiment remains net bullish for FHLC into Q2 2026, backed by Super Investors like Ken Fisher and Cliff Asness holding meaningful positions, with Asness even opening a new position during the quarter for a total net inflow of over $233,000 among tracked gurus. This institutional accumulation aligns with a portfolio P/E of 18.67x, which sits below the broader category average of 20.61x and offers a reasonable entry valuation.

When evaluating FHLC against specialty peers like the Invesco Pharmaceuticals ETF (PJP), the structural cost advantage is impossible to ignore. FHLC charges an expense ratio of just 0.08% compared to PJP's 0.57%, while offering a slightly higher dividend yield of 1.29%. For long-term core allocations, running the cost-compounding math heavily favors Fidelity's vehicle, provided an investor is comfortable with the broader MSCI USA IMI Health Care Index composition.

In building our fundamental thesis, we cannot overlook the single-name concentration risk embedded in FHLC. Eli Lilly commands a heavy 13.74% weight in the portfolio. Any sharp regulatory shifts, clinical pipeline disappointments, or pricing battles over GLP-1 weight-loss medications will disproportionately sway this broad index fund, turning what is supposed to be a diversified defensive sector play into an implicit bet on a single pharmaceutical giant.